Please login to your online account to display your discounted pricing

Promega™ P450-Glo™ CYP1A2 Induction/Inhibition Assay

A homogeneous, luminescent method to measure cytochrome P450 activity

$182.97 - $535.00

Specifications

Detection Method Homogeneous, Luminescent
For Use With (Application) For measuring cytochrome P450 activity
For Use With (Equipment) For 384-well format
Storage Requirements All components at -20°C, except Luciferin-PPXE, which must be stored at -70°C
View More Specs
Includes:  Luciferin-1A2 (30μL), 500X D-Cysteine (100μL), luciferin detection reagent and reconstitution buffer.
Products
Catalog Number Mfr. No. Quantity Price Quantity    

PRV8421

 
promega™
V8421
10mL Each for $182.97

PRV8422

 
promega™
V8422
50mL Each for $535.00
Description & Specifications

Specifications

Detection Method Homogeneous, Luminescent
For Use With (Application) For measuring cytochrome P450 activity
For Use With (Equipment) For 384-well format
Storage Requirements All components at -20°C, except Luciferin-PPXE, which must be stored at -70°C

A conventional cytochrome P450 reaction is performed by incubating the cytochrome P450 and a luminogenic cytochrome P450 substrate. The substrates of the P450-Glo Assays are derivatives of beetle luciferin, which are not substrates for luciferase but are converted by cytochrome P450s to luciferin, which in turn reacts with luciferase to produce light. The amount of light produced is directly proportional to cytochrome P450 activity.

  • Contains Luciferin-1A2
  • For use in cell-based applications
  • Measures CYP Inhibition, recombinant CYP activity, native CYP activity, CYP induction
  • Rapid method provides greater sensitivity
  • No fluorescence interference yields low false-positive rate and signal stability
  • Features cell permeability, DMSO tolerance
  • Scalable to 384-well format

  • Measure recombinant CYP1A2 activities in membrane fractions from heterologous expression systems, such as Sf9 cells and E. coli
  • Measure native CYP1A2 activity in cells and microsomal fractions from cells and tissues
  • Screen drugs and new chemical entities for their capacity to modulate CYP450 activities in native or recombinant fractions